Calcium Electroporation as a Treatment for Cutaneous and Subcutaneous Malignant Tumours

Cancer Clinical Trial

— CaEP-R  

Official title:

Phase II Investigation of Calcium Electroporation as a Treatment for Cutaneous and Subcutaneous Malignant Tumours

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04225767
• Other study ID #: REG-115-2019
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: February 18, 2020
• Est. completion date: August 1, 2023

Study information

• Verified date: December 2022
• Source: Zealand University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase II Investigation of Calcium Electroporation as a Treatment for Cutaneous and Subcutaneous Malignant Tumours.

Description:

This will be a non-randomized phase II trial with the objective of evaluating the clinical response rate of calcium electroporation treatment of malignant tumours of the skin and assessing treatment impact on quality of life. This study will investigate the response rate of calcium electroporation treatment of skin metastases and malignant wounds in a real-world setting, in three different cancer centres in Northern Europe. The centres aim to treat a total of 30 patients with cancer in the skin of any histology. The patients will be treated once and followed with regular examinations for 12 months, starting from first treatment day. All patients will have been offered the standard of care and all available alternatives before entering the protocol. Calcium electroporation will not be compared to other means of treatment. The primary endpoint of this study is to evaluate the clinical overall response rate of calcium electroporation treatment of malignant tumours of the skin after two months. A subset of patients will undergo MR scans after treatment and another subset of patients will be interviewed regarding treatment impact on quality of life.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 19
• Est. completion date: August 1, 2023
• Est. primary completion date: January 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Trial subject = 18 years.
• Trial subject must be able to understand the participant information.
• Histologically verified cutaneous or subcutaneous, primary or secondary cancer of any histology.
• The patient must have been offered other relevant standard treatment for their cancer disease.
• The patient can undergo any simultaneous medical treatment (endocrine therapy, chemotherapy, immunotherapy etc.) if progressive or stable disease is present after a treatment period of two months or more.
• The patient can undergo radiation therapy, provided that the treatment field does not involve treated area.
• Performance status ECOG/WHO =2.
• At least one cutaneous or subcutaneous tumour measuring up to 3 cm.
• Both men and women who are sexually active must use safe contraception (contraceptive coil, deposit injection of gestagen, subdermal implantation, hormonal vaginal ring or transdermal patch).
• Signed informed consent.

Exclusion Criteria:

• Pregnancy or lactation

Related Conditions & MeSH terms

• Cancer
• Neoplasms

Intervention

Combination Product:
• Calcium electroporation
Patients with cutaneous or subcutaneous malignant tumours will be treated with calcium electroporation, i.e. intratumoral injection of calcium followed by electroporation by electric pulses applied directly to the tumor.

Locations

Country	Name	City	State
Denmark	Zealand University Hospital	Næstved	Region Zealand

Sponsors (4)

Lead Sponsor	Collaborator
Zealand University Hospital	University College Absalon, University Hospital Schleswig-Holstein, Vejle Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumour response (size)	Response rate will be defined as number of responding lesions (partial or complete response) relative to treated lesions evaluated by changes in size (mm) by clinical examination with caliper measurement. Tumor response will be further documented using clinical photography.	2 months
Secondary	Treatment response up to 12 months (size)	Evaluate treatment response at month 1, 3, 4, 6 and 12 in addition to evaluating treatment response after 2 months. Response rate will be defined as number of responding lesions (partial or complete response) relative to treated lesions evaluated by changes in size (mm) by clinical examination with caliper measurement. Tumor response will be further documented using clinical photography.	13 months
Secondary	Assessment of residual tumor from biopsies after 1 year	Assess tumour and surrounding tissue response to treatment from biopsies of the treated area after 1 year. Microscopy assessment of histopathological regressive changes (eg. % tumor cells and fibrosis).	12 months
Secondary	MRI scans to verify treatment and evaluate tumour changes after treatment	Assess response after treatment on MRI scans on a subset of patients before and immediately after treatment, as well as after 2 months using diffusion-weighted magnetic resonance imaging (DW-MRI) as a method to monitor electroporated tissue, using the concept of the apparent diffusion coefficient (ADC).	2 months
Secondary	Evaluation of patient quality of life before and after treatment using EORTC Questionnaires.	Evaluate patient quality of life before treatment, after 2 months and after 1 year through EORTC QLQ-C15-PAL Core questionnaires evaluating cancer-related symptoms on a scale from 1-4 (not at all-very much) as well as overall quality of life on a scale from 1-7 (very poor-excellent).	13 months
Secondary	Systemic immunologic response evaluated by routine scans	Investigate any sign of systemic immunologic response from any routine scans (MRI, PET-CT etc.) before and after treatment in the inclusion period by tumor size and TNM stage.	12 months
Secondary	Response according to tumour histology	To list response rates and response duration according to tumour histology.	12 months
Secondary	Remission	To determine complete and partial remissions for all tumours treated. Response rate will be defined as number of responding lesions (partial or complete response) relative to treated lesions evaluated by changes in size (mm) by clinical examination with caliper measurement. Tumor response will be further documented using clinical photography.	12 months
Secondary	Individual response	To determine rate of response for each individual patient.	12 months
Secondary	Importance of irradiation	To investigate response (overall, as well as complete and partial) depending whether the treated tumour was in a previously irradiated area. Response rate will be defined as number of responding lesions (partial or complete response) relative to treated lesions evaluated by changes in size (mm) by clinical examination with caliper measurement. Tumor response will be further documented using clinical photography.	12 months
Secondary	Current measurement	To measure current during treatment as measured by the pulse generator.	1 day
Secondary	Evaluation of changes in quality of life through qualitative interview	Analyses of qualitative interviews (in a subset of patients) performed before- and 2 months after treatment that include measures related to patient experience and impact on quality of life.	2 months